Totality of evidence for biosimilar pegfilgrastim Ziextenzo

Biosimilars/Research | Posted 09/09/2022 post-comment0 Post your comment

Agarwala et al. have recently published a review on the totality of evidence (ToE) for the biosimilar pegfilgrastim Ziextenzo® (LA-EP2006) matching the European Union- (EU) and US-reference biological pegfilgrastim Neulasta® (marketed by Amgen) [1].

Pegfilgrastim V16B19

Ziextenzo® is a recombinant methionyl human granulocyte colony-stimulating factor (G-CSF) with a covalent conjugation of polyethylene glycol (PEG) indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy [2, 3].

A critical assessment of quality attributes was carried out, focusing on the highest impact on clinical outcome to ensure desired biosimilar quality. The ToE was comprised of preclinical analysis including structural and functional attributes as well as clinical studies confirming matching results in efficacy, safety and immunogenicity to its reference medicine. State-of-the-art techniques assessed physiochemical attributes showing identical primary structure and pegylation site, indistinguishable higher-order structure, similar variant and impurity profiles covering end of shelf life, molecular size variants, and formulation. Similar biological activity was demonstrated including potency and binding affinity to the G-CSF receptor. Quantitative quality attributes were based on broader batch ranges to increase comprehensive statistical evaluation.

Clinical pharmacokinetic (PK) and pharmacodynamic (PD) similarity of biosimilar pegfilgrastim Ziextenzo with reference pegfilgrastim sourced from the EU and US was demonstrated by a key randomized, double‐blind, single‐dose, multicentre study using a three-way crossover six-sequence design with 576 healthy male and female subjects [4]. This was supplemented by two randomized, double-blind phase III confirmatory clinical studies in patients with breast cancer under chemotherapy matching the reference pegfilgrastim in terms of efficacy [5, 6]. The equivalence criteria with a defined margin of ±1 day were met for the primary endpoint (mean duration of severe neutropenia [DNS]) in both studies, the difference between biosimilar pegfilgrastim Ziextenzo and reference medicine comprising only 0.04 days [6]. Safety and immunogenicity profiles showed no clinically relevant differences, with similar incidences of treatment-related adverse events and no detection of treatment-related binding and neutralizing antibodies including a six-month follow up period (PROTECT-1) [5, 6].

According to Agarwala et al., the ToE of biosimilar pegfilgrastim Ziextenzo including extensive clinical data confirms equivalent efficacy and safety and biosimilarity between Ziextenzo® and its EU- and US-reference pegfilgrastim. Therefore, biosimilar pegfilgrastim Ziextenzo® could be used as a safe and effective treatment option in patients for all eligible indications, concluded the authors.

Conflict of interest
The authors of the research paper [1] declared that they are either current or former employees of Sandoz. For full details of the authors’ conflict of interest, see the research paper [1].

Abstracted by Dr Sebastian Howe, Global Medical Manager Oncology, Hexal AG, Germany; Spanish version translated by Daniel Freire, Head Medical Affairs Latin America, Sandoz Brazil.

Editor’s Comment
Readers interested to learn more about regulatory context and future of biosimilar pegfilgrastim are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Pelmeg®, a biosimilar pegfilgrastim developed in the context of evolving regulatory guidelines

Perspectives on the future of pegfilgrastim biosimilars

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more

Readers interested in contributing a research or perspective paper to GaBI Journal – an independent, peer reviewed academic journal – please send us your submission here

GaBI Journal Citation Impact
2.2 – CiteScore 2021 (calculated on 5 May 2022)
2.2 – CiteScoreTracker 2022 (Last updated on 5 August 2022)

Submit a manuscript to GaBI Journal

Related articles
FDA approves pegfilgrastim and rituximab biosimilars

Pegfilgrastim biosimilar Udenyca demonstrated similar immunogenicity to Neulasta

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Panorama regulatorio de los biosimilares en América Latina

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Panorama regulatorio de los biosimilares en América Latina

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  

References
1. Sanjiv SA, Ulrich N, Xinghua G, et al. A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006). Curr Med Res Opin. 2022;38(6):999-1009.
2. European Medicines Agency. Summary of product characteristics. Ziextenzo [homepage on the Internet]. [cited 2022 Sep 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/ziextenzo-epar-product-information_en.pdf
3. U.S. Food and Drug Administration. Ziextenzo prescribing information [homepage on the Internet]. [cited 2022 Sep 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761045lbl.pdf?msclkid=1994df54cf7511ec97566f9e44834a60
4. Bellon A, Wang J, Skerjanec A, et al. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics. Br J Clin Pharmacol. 2020;86(6):1139-49.
5. Harbeck N, Lipatov O, Frolova M, et al. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol. 2016;12(11):1359-67.
6. Blackwell K, Gascon P, Jones CM, et al. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Ann Oncol. 2017;28(9):2272-7.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Regulatory landscape for biosimilars in Latin America
Latin America 1638px
Biosimilars/Research Posted 09/09/2022
Access to biosimilars for cancer treatments in Latin America
Cancer Cell V13I20
Biosimilars/Research Posted 26/08/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010